Hematologic Oncology

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses frail and elderly patients with multiple myeloma.

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the use of ropeginterferon alfa-2b in myeloproliferative neoplasms (MPNs).

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses a study of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasms.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Srdan Verstovsek, MD, PhD, discusses the use of interferon in rare blood diseases.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

The FDA has granted a priority review to a supplemental new drug application for ivosidenib for the frontline treatment of patients IDH1-mutant acute myeloid leukemia who are ineligible for standard chemotherapy.

Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.

The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.